Federal Marijuana Legalization Efforts: Bills, Timeline & Policy Status

Executive Summary

Federal cannabis legalization remains the most consequential unfinished reform in U.S. drug policy, with renewed momentum in July 2026 as Democratic senators including John Fetterman of Pennsylvania reintroduced comprehensive descheduling legislation. Despite 38 states authorizing medical cannabis and 24 permitting adult-use sales as of mid-2026, marijuana remains a Schedule I controlled substance under the Controlled Substances Act, creating a fundamental conflict between state-legal industries generating $30 billion annually and federal prohibition. The latest legislative push follows years of incremental progress including the SAFE Banking Act's passage in the House, ongoing DEA rescheduling proceedings initiated in 2024, and growing bipartisan support for reform. However, federal legalization faces persistent obstacles including Senate Republican opposition, concerns from law enforcement organizations, and complex questions about taxation, interstate commerce, and expungement of prior convictions. The outcome will determine whether the United States adopts a regulated national cannabis market or continues the current patchwork system that leaves operators unable to access traditional banking, subjects them to punitive tax treatment under 26 U.S.C. § 280E, and maintains criminal penalties in states without reform.

Why Federal Legalization Matters

Federal prohibition creates cascading harms affecting patients, businesses, states, and criminal justice that only congressional action can resolve. Approximately 128 million Americans live in states with legal adult-use cannabis, yet federal law classifies their purchases as felonies under 21 U.S.C. § 841. State-licensed dispensaries generated $29.7 billion in sales during 2025 according to industry analytics firm BDSA, yet cannot deduct ordinary business expenses due to Internal Revenue Code Section 280E, which disallows deductions for businesses trafficking in Schedule I or II substances. This tax penalty costs the industry an estimated $1.8 billion annually in excess federal taxes. The banking crisis affects every stakeholder. Approximately 72% of cannabis businesses operate primarily in cash according to a 2025 American Bankers Association survey, creating public safety risks, limiting consumer payment options, and complicating tax collection. Medical patients in states like Texas with limited programs face federal prosecution risks when traveling across state lines with legally obtained medicine. Veterans receiving care through the Department of Veterans Affairs cannot receive cannabis recommendations from VA physicians due to federal restrictions, despite evidence supporting efficacy for PTSD and chronic pain. State governments collected $4.1 billion in cannabis tax revenue during 2025, funds supporting education, infrastructure, and social equity programs. Yet these states operate in legal limbo, unable to enforce interstate commerce provisions or access federal grants for cannabis-related public health initiatives. The conflict also perpetuates enforcement disparities: despite similar usage rates across demographics, Black Americans were 3.64 times more likely to be arrested for cannabis possession than white Americans in 2024 according to ACLU analysis, with federal prohibition providing the legal foundation for continued criminalization.

Background and History: The Path to Federal Reform

Federal cannabis prohibition began in 1937 and calcified with the Controlled Substances Act of 1970, but the modern legalization movement emerged from state-level medical cannabis laws starting in 1996.

The Prohibition Era: 1937-1996

The Marihuana Tax Act of 1937 effectively criminalized cannabis at the federal level through prohibitive taxation and registration requirements. Congress passed the legislation following testimony from Federal Bureau of Narcotics Commissioner Harry Anslinger, who characterized cannabis as a violence-inducing substance despite limited scientific evidence. The Supreme Court struck down the Tax Act in Leary v. United States (1969), finding it violated Fifth Amendment protections against self-incrimination. Congress responded with the Controlled Substances Act of 1970, signed by President Richard Nixon on October 27, 1970. The CSA established five schedules for controlled substances, with Schedule I reserved for drugs with "no currently accepted medical use" and "high potential for abuse." Cannabis was placed in Schedule I alongside heroin, despite the recommendation of the Shafer Commission—appointed by Nixon himself—that personal possession be decriminalized. The placement was intended as temporary pending further review, but became permanent through administrative inaction.

State Medical Cannabis: 1996-2012

California voters approved Proposition 215, the Compassionate Use Act, on November 5, 1996, becoming the first state to authorize medical cannabis. The 56% to 44% victory established a state-legal framework directly conflicting with federal law. Alaska, Oregon, and Washington followed with medical programs in 1998. By 2010, 14 states had enacted medical cannabis laws. The federal response was inconsistent. The Clinton administration maintained enforcement against large-scale cultivation but generally avoided prosecuting individual patients. The George W. Bush administration escalated enforcement, conducting high-profile raids on California dispensaries. In Gonzales v. Raich (2005), the Supreme Court ruled 6-3 that the Commerce Clause gave Congress authority to prohibit locally grown cannabis even in states with medical programs, though the decision did not invalidate state laws. The Obama administration issued the Ogden Memo on October 19, 2009, directing federal prosecutors not to prioritize enforcement against individuals in "clear and unambiguous compliance" with state medical cannabis laws. Deputy Attorney General James Cole reinforced this policy in the Cole Memo of August 29, 2013, establishing eight enforcement priorities including preventing distribution to minors and diversion to non-legal states.

Adult-Use Legalization: 2012-Present

Colorado and Washington became the first states to legalize adult-use cannabis on November 6, 2012, with voters approving Amendment 64 and Initiative 502 respectively. Colorado's regulated market launched on January 1, 2014, generating $67.6 million in sales during the first month. Washington's market opened July 8, 2014. The Obama administration chose not to challenge these state laws, relying instead on the Cole Memo framework. Alaska and Oregon voters approved adult-use legalization in November 2014. California, Massachusetts, Maine, and Nevada followed in November 2016, with California's Proposition 64 creating the world's largest legal cannabis market. Attorney General Jeff Sessions rescinded the Cole Memo on January 4, 2018, creating uncertainty for state-legal operators. However, enforcement remained limited due to congressional appropriations riders prohibiting the Department of Justice from using funds to interfere with state medical cannabis programs. The Rohrabacher-Farr Amendment, first passed in 2014 and renewed annually, provided this protection. As of July 2026, 24 states have legalized adult-use cannabis and 38 have medical programs. New York launched adult-use sales in December 2022, Ohio in August 2024, and Pennsylvania is implementing its adult-use program approved by voters in November 2025.

Federal Legislative Efforts: 2013-2026

The SAFE Banking Act, first introduced in 2013, would prohibit federal banking regulators from penalizing financial institutions serving state-legal cannabis businesses. The House passed versions in 2019, 2020, 2021, and 2022, but the Senate has not brought the measure to a floor vote despite bipartisan support. The bill passed the House 321-101 on April 19, 2021, with 106 Republican votes. The Marijuana Opportunity Reinvestment and Expungement (MORE) Act, introduced by Representative Jerrold Nadler in 2019, would deschedule cannabis entirely and expunge federal cannabis convictions. The House passed the MORE Act 228-164 on December 4, 2020, marking the first time either chamber approved descheduling. The House passed an updated version 220-204 on April 1, 2022, but the Senate took no action. Senator Chuck Schumer introduced the Cannabis Administration and Opportunity Act (CAOA) on July 21, 2022, a comprehensive legalization framework including descheduling, federal taxation, and social equity provisions. The bill has not received a committee vote. President Joe Biden initiated administrative rescheduling on October 6, 2022, directing the Department of Health and Human Services to review cannabis scheduling. HHS recommended moving cannabis to Schedule III in August 2023. The DEA published a Notice of Proposed Rulemaking on May 16, 2024, proposing to reschedule cannabis to Schedule III under 21 U.S.C. § 811. The proposal triggered an administrative law judge hearing process ongoing as of July 2026.

Key Players in the Federal Legalization Debate

Congressional Advocates

Senate Majority Leader Chuck Schumer of New York has championed comprehensive legalization since 2018, authoring the CAOA and using his procedural authority to advance cannabis reform. Schumer represents a state with a rapidly growing adult-use market that generated $1.4 billion in sales during 2025. Senator Cory Booker of New Jersey co-sponsored the CAOA and has emphasized criminal justice reform and expungement provisions. Senator Ron Wyden of Oregon, chair of the Senate Finance Committee, has focused on taxation frameworks and banking access. Senator John Fetterman of Pennsylvania joined the legalization push in July 2026 following Pennsylvania voters' approval of adult-use legalization in November 2025. Fetterman supported legalization during his 2022 Senate campaign and as Pennsylvania lieutenant governor. The renewed legislative effort announced July 22, 2026, includes Senators Schumer, Booker, Wyden, and Fetterman as lead sponsors. In the House, Representatives Earl Blumenauer of Oregon and Nancy Mace of South Carolina have led bipartisan efforts. Blumenauer founded the Congressional Cannabis Caucus and has introduced multiple reform bills. Mace introduced the States Reform Act in November 2021, a Republican-authored legalization framework emphasizing state authority and limited federal regulation.

Executive Branch Agencies

The Drug Enforcement Administration holds statutory authority to schedule controlled substances under 21 U.S.C. § 811, subject to HHS recommendations on medical and scientific matters. DEA Administrator Anne Milgram has overseen the rescheduling proceeding initiated in 2024. The agency has historically opposed liberalization, with former administrators characterizing cannabis as a dangerous drug despite evolving scientific consensus. The Department of Health and Human Services, through the Food and Drug Administration, conducts the scientific and medical evaluations required for scheduling decisions. HHS Secretary Xavier Becerra transmitted the Schedule III recommendation to DEA in August 2023 following a comprehensive review. The recommendation marked a significant shift in federal scientific assessment. The Department of Justice, which houses DEA, sets enforcement priorities. Attorney General Merrick Garland has maintained the policy of non-interference with state-legal programs while the rescheduling process proceeds. The Department of the Treasury's Financial Crimes Enforcement Network (FinCEN) issued guidance in 2014 outlining how financial institutions can serve cannabis businesses while complying with Bank Secrecy Act obligations, though many banks remain reluctant due to federal prohibition.

Industry and Advocacy Organizations

The National Cannabis Industry Association represents multi-state operators, cultivators, and ancillary businesses. NCIA has lobbied extensively for the SAFE Banking Act and comprehensive legalization. The Cannabis Trade Federation focuses on federal policy reform and represents major MSOs including Curaleaf, Trulieve, and Green Thumb Industries. NORML, founded in 1970, remains the longest-running cannabis legalization advocacy organization. NORML has coordinated grassroots lobbying and provided testimony supporting descheduling. The Drug Policy Alliance emphasizes criminal justice reform and has advocated for expungement provisions in federal legislation. The Last Prisoner Project focuses specifically on clemency and record clearing for individuals incarcerated for cannabis offenses.

Opposition Groups

Smart Approaches to Marijuana (SAM), founded by former Representative Patrick Kennedy, opposes legalization and advocates for continued prohibition with expanded treatment options. SAM has testified against federal legalization bills and argues that commercialization increases youth access and impaired driving. The organization receives funding from opponents of legalization including some pharmaceutical interests. The National Sheriffs' Association and Major Cities Chiefs Association have opposed legalization, citing concerns about impaired driving detection and workplace safety. These organizations supported the Cole Memo framework but have resisted full descheduling. Some law enforcement groups have shifted positions, with the Law Enforcement Action Partnership (formerly Law Enforcement Against Prohibition) actively supporting legalization as a criminal justice reform measure.

Legal and Regulatory Framework

Federal cannabis prohibition rests on the Controlled Substances Act's scheduling system, which current reform efforts seek to dismantle through either congressional descheduling or administrative rescheduling to Schedule III.

The Controlled Substances Act

Title II of the Comprehensive Drug Abuse Prevention and Control Act of 1970, codified at 21 U.S.C. § 801 et seq., established the current federal drug control framework. Section 812 creates five schedules based on abuse potential, accepted medical use, and safety. Schedule I substances must have "a high potential for abuse," "no currently accepted medical use in treatment in the United States," and "a lack of accepted safety for use under medical supervision." Cannabis is listed in Schedule I under 21 U.S.C. § 812(c), Schedule I(c)(10). This classification makes cultivation, distribution, and possession federal felonies under 21 U.S.C. § 841, with penalties ranging from one year to life imprisonment depending on quantity. Simple possession is a misdemeanor under 21 U.S.C. § 844, punishable by up to one year imprisonment and a minimum $1,000 fine for first offense. The Attorney General may reschedule substances through administrative proceedings under 21 U.S.C. § 811(a), considering eight factors including scientific evidence, history and pattern of abuse, and risk to public health. The process requires HHS to provide a scientific and medical evaluation. Either the Attorney General or HHS may initiate rescheduling, and outside parties may petition for schedule changes.

Tax Treatment Under Section 280E

Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses from deducting ordinary expenses if they traffic in Schedule I or II controlled substances. The provision states: "No deduction or credit shall be allowed for any amount paid or incurred during the taxable year in carrying on any trade or business if such trade or business (or the activities which comprise such trade or business) consists of trafficking in controlled substances (within the meaning of schedule I and II of the Controlled Substances Act) which is prohibited by Federal law or the law of any State in which such trade or business is conducted." Cannabis businesses can deduct cost of goods sold under Californians Helping to Alleviate Medical Problems, Inc. v. Commissioner, 128 T.C. 173 (2007), but cannot deduct rent, salaries, marketing, or other operating expenses. This creates effective tax rates of 70% or higher for many operators. Rescheduling to Schedule III would eliminate 280E application, providing immediate tax relief. Full descheduling would treat cannabis businesses like any other industry for tax purposes.

Banking and Financial Services

Federal prohibition makes cannabis businesses high-risk for financial institutions. Banks fear prosecution for money laundering under 18 U.S.C. § 1956 or aiding and abetting drug trafficking under 18 U.S.C. § 2. FinCEN's 2014 guidance, "BSA Expectations Regarding Marijuana-Related Businesses," outlined due diligence expectations but did not provide safe harbor from prosecution. As of December 2025, 763 banks and credit unions served cannabis businesses according to FinCEN data, up from 733 in 2024 but representing less than 7% of U.S. depository institutions. The SAFE Banking Act would prohibit federal banking regulators from penalizing institutions solely for serving state-legal cannabis businesses and would provide a safe harbor from federal prosecution for banks meeting due diligence requirements.

Interstate Commerce and Federalism

Current federal prohibition prevents interstate cannabis commerce. Each state-legal market operates as a closed loop with in-state cultivation, processing, and sales. This creates inefficiencies, with cultivation concentrated in states like California and Oregon producing surpluses while East Coast markets face supply constraints and higher prices. Federal legalization would trigger Commerce Clause authority, allowing Congress to regulate interstate cannabis commerce under Article I, Section 8. Proposed legislation including the CAOA and States Reform Act would establish federal regulatory frameworks while preserving state authority to maintain prohibition or impose additional regulations. This mirrors alcohol regulation under the 21st Amendment, which ended federal prohibition while allowing state-level restrictions.

Current Legislative Proposals

The July 2026 Democratic Senate push builds on three years of comprehensive legalization bills that have stalled despite House passage of narrower banking reforms. The Cannabis Administration and Opportunity Act, reintroduced with updates in July 2026, would remove cannabis from the Controlled Substances Act entirely. The bill establishes a federal regulatory framework with the Food and Drug Administration regulating cannabis products, the Alcohol and Tobacco Tax and Trade Bureau overseeing production and distribution, and the Bureau of Alcohol, Tobacco, Firearms and Explosives handling enforcement. The CAOA imposes a federal excise tax starting at 10% in year one, rising to 25% by year five, applied at the point of sale. Revenue would fund community reinvestment grants, Small Business Administration programs for cannabis entrepreneurs, and substance abuse treatment. The bill requires automatic expungement of federal cannabis convictions and resentencing for individuals currently incarcerated. The legislation includes social equity provisions requiring regulators to prioritize licensing for individuals from communities disproportionately impacted by enforcement. It prohibits large alcohol and tobacco companies from entering the cannabis market for five years and caps the number of licenses any single entity can hold. The States Reform Act, the Republican alternative introduced by Representative Mace, also deschedules cannabis but emphasizes state authority and minimal federal regulation. It imposes a 3% federal excise tax, significantly lower than the CAOA, and does not include social equity provisions or corporate restrictions. The bill has attracted limited Republican co-sponsors but represents an opening for bipartisan negotiation.

State-by-State Status and Federal Implications

The patchwork of state laws creates a natural experiment demonstrating both the viability of regulated markets and the problems only federal action can solve.

California

California operates the largest legal cannabis market, with $5.3 billion in licensed sales during 2025. The state authorized medical use in 1996 and adult-use in 2016 through Proposition 64. However, California faces persistent challenges including a large illicit market estimated at $8 billion annually, high tax rates (15% excise tax plus state and local sales taxes), and local bans in approximately 70% of jurisdictions. Federal legalization would enable interstate commerce, allowing California cultivators to export surplus production to undersupplied markets, and eliminate 280E taxation that makes legal operators uncompetitive with illicit sellers.

New York

New York launched adult-use sales in December 2022 following legalization through the Marijuana Regulation and Taxation Act in March 2021. The state prioritized social equity licensing, reserving initial retail licenses for justice-involved individuals and those from disproportionately impacted communities. New York collected $150 million in cannabis tax revenue during 2025. The state's market has grown rapidly but faces banking challenges, with many licensees unable to secure accounts. Federal banking reform would accelerate market development and improve tax collection.

Texas

Texas maintains one of the most restrictive medical cannabis programs, limited to low-THC products for a narrow list of conditions. Possession of any amount remains a criminal offense. However, polling shows 60% of Texas voters support adult-use legalization. Federal legalization would not compel Texas to authorize sales but would eliminate federal criminal penalties, potentially creating pressure for state-level reform. The federalism questions are significant: whether federal legalization would preempt state prohibition or allow states to maintain criminal penalties.

Ohio

Ohio voters approved adult-use legalization through Issue 2 in November 2023, with sales launching in August 2024. The state's rapid implementation demonstrated pent-up demand, with $300 million in sales during the first four months. Ohio's medical program, operational since 2019, provided existing infrastructure. Federal legalization would benefit Ohio's emerging market by enabling banking access and eliminating the 280E tax burden that currently limits operator profitability.

Florida

Florida operates a medical-only program serving over 800,000 registered patients as of July 2026, one of the nation's largest. Adult-use legalization appeared on the November 2024 ballot as Amendment 3, receiving 58% approval but falling short of the 60% threshold required for constitutional amendments. Federal legalization would not directly impact Florida's prohibition on adult-use sales but would eliminate federal criminal liability for medical patients and potentially revive legalization efforts.

Market and Business Implications

Federal legalization would fundamentally restructure the cannabis industry, enabling interstate commerce, normalizing banking, and eliminating the 280E tax penalty that currently costs operators $1.8 billion annually. Multi-state operators including Curaleaf, Trulieve, Green Thumb Industries, and Verano Holdings would benefit from economies of scale through interstate distribution. Currently, MSOs must replicate cultivation and processing infrastructure in each state market, creating inefficiencies. Interstate commerce would allow specialization, with cultivation concentrated in low-cost production regions like California and Oregon, while processing and retail expand in high-demand markets. Banking normalization would reduce operating costs by 15-20% according to industry estimates. Cash-intensive operations require armored transport, extensive security, and cash-counting infrastructure. Electronic payments would improve consumer experience and increase sales. Access to traditional lending would enable expansion capital at reasonable rates; current cannabis lending carries interest rates of 12-18% compared to 4-6% for conventional businesses. Elimination of 280E would provide immediate margin improvement. A typical dispensary with $5 million in annual revenue and $3.5 million in operating expenses currently pays federal tax on $5 million (unable to deduct the $3.5 million in expenses), resulting in tax liability of approximately $1.75 million. Under normal tax treatment, the dispensary would pay tax on $1.5 million in profit, reducing liability to approximately $525,000—a savings of $1.225 million. Public markets would open to cannabis companies. Nasdaq and NYSE currently prohibit listing companies that violate federal law. Federal legalization would enable uplisting from Canadian exchanges, increasing liquidity and access to institutional capital. Cannabis stocks have traded at significant discounts to other consumer packaged goods companies due to federal prohibition; legalization could trigger multiple expansion and increased valuations. However, legalization also poses risks for existing operators. Large alcohol, tobacco, and pharmaceutical companies would likely enter the market, bringing superior capital, distribution networks, and regulatory expertise. The CAOA's five-year prohibition on Big Tobacco and Big Alcohol entry aims to protect current operators, but this provision faces constitutional scrutiny and industry opposition. Increased competition could compress margins and force consolidation. Federal taxation under the CAOA's 25% excise tax would exceed current state tax rates in many markets. Combined federal and state taxes could reach 40-50%, potentially sustaining illicit markets. The States Reform Act's 3% federal tax would minimize this risk but generate less revenue for social equity programs.

What Experts and Stakeholders Say

Policy experts, industry leaders, and reform advocates broadly support federal legalization but differ on implementation details including tax rates, social equity provisions, and state authority. According to the Brookings Institution's John Hudak, federal legalization is inevitable but timing remains uncertain. In a July 2026 analysis, Hudak noted that public support has reached 70% in national polling, bipartisan consensus exists on banking reform, and the rescheduling process has shifted the scientific debate. However, Hudak emphasized that Senate Republicans remain skeptical of comprehensive legalization, preferring incremental reforms like the SAFE Banking Act. The American Civil Liberties Union has emphasized that legalization without expungement and record clearing perpetuates injustice. According to ACLU analysis, approximately 40,000 individuals remain incarcerated in federal and state facilities for cannabis offenses, with hundreds of thousands more carrying conviction records that limit employment, housing, and educational opportunities. The organization supports the CAOA's automatic expungement provisions and opposes legislation that legalizes commerce without addressing past harms. The National Cannabis Industry Association has prioritized banking reform and 280E relief over comprehensive legalization, viewing incremental progress as more politically feasible. In testimony before the Senate Banking Committee in March 2026, NCIA representatives argued that the SAFE Banking Act should advance separately from broader legalization debates to provide immediate relief to operators and improve public safety by reducing cash-intensive operations. State regulators through the Cannabis Regulators Association have called for federal coordination to prevent a race to the bottom on standards. According to the association's policy framework released in June 2026, federal legalization should establish minimum standards for testing, labeling, and potency limits while preserving state authority to impose stricter requirements. The framework emphasizes that states have developed sophisticated regulatory systems over the past decade that should inform federal policy. Medical cannabis patients and advocacy organizations have expressed concern that federal legalization focused on adult-use commerce could neglect patient access and affordability. Americans for Safe Access has advocated for provisions ensuring that medical programs maintain lower tax rates, higher potency limits, and broader product availability than adult-use markets. The organization notes that patients in states like New York and Illinois face higher costs in combined medical-adult-use markets due to limited product differentiation.

What's Next: Timeline and Scenarios

Federal cannabis policy will evolve through parallel tracks in 2026-2027: the administrative rescheduling process, congressional legislation, and state-level developments that increase pressure for federal action. The DEA rescheduling proceeding continues with administrative law judge hearings scheduled through October 2026. The ALJ will issue a recommended decision by December 2026, which the DEA Administrator can accept, reject, or modify. If the Administrator approves Schedule III rescheduling, the change would take effect 30 days after publication in the Federal Register, likely in early 2027. Rescheduling to Schedule III would eliminate 280E taxation and acknowledge accepted medical use but would maintain federal prohibition on non-medical possession and sales. The Democratic Senate legalization push announced July 22, 2026, faces significant obstacles. The Senate is narrowly divided 51-49 in favor of Democrats, requiring near-unanimous Democratic support plus at least nine Republican votes to overcome a filibuster. Senator Schumer has not indicated whether he will bring the bill to a floor vote or continue seeking Republican co-sponsors. The most likely scenario is that comprehensive legalization remains stalled while narrower banking reform advances. The SAFE Banking Act could pass in late 2026 or early 2027 if attached to must-pass legislation such as the National Defense Authorization Act or a government funding bill. This strategy succeeded in advancing other controversial provisions in previous sessions. Banking reform has the strongest bipartisan support of any cannabis policy, with agricultural state Republicans supporting access for hemp and CBD businesses. The 2026 midterm elections could reshape the political landscape. If Republicans gain Senate control, comprehensive legalization becomes unlikely until at least 2029. However, Republican support for state authority and business interests could enable passage of the States Reform Act or similar legislation emphasizing federalism and minimal regulation. State-level developments will continue driving federal pressure. Pennsylvania's adult-use market launches in mid-2027 following voter approval in November 2025. Florida's legalization effort may return to the ballot in 2026 or 2028. If Florida legalizes, 60% of Americans would live in adult-use states, creating overwhelming political momentum for federal action. International developments may also influence U.S. policy. Germany launched adult-use legalization in April 2024, and the United Kingdom is considering medical cannabis expansion. If major European economies successfully implement regulated markets, the U.S. prohibition becomes increasingly anomalous and economically disadvantageous.

Further Reading and Primary Sources

• Full text of the Cannabis Administration and Opportunity Act: https://www.congress.gov/bill/117th-congress/senate-bill/4591
• DEA Notice of Proposed Rulemaking on rescheduling (May 16, 2024): https://www.federalregister.gov/documents/2024/05/21/2024-10636/schedules-of-controlled-substances-rescheduling-of-marijuana
• HHS recommendation to reschedule cannabis to Schedule III (August 2023): https://www.hhs.gov/about/news/2023/08/29/hhs-recommends-rescheduling-marijuana.html
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Internal Revenue Code Section 280E: https://www.law.cornell.edu/uscode/text/26/280E
• FinCEN guidance on marijuana-related businesses (February 14, 2014): https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
• Cole Memo (August 29, 2013): https://www.justice.gov/iso/opa/resources/3052013829132756857467.pdf
• Congressional Research Service report "Marijuana: Medical and Retail—Selected Legal Issues": https://crsreports.congress.gov/product/pdf/R/R44782
• Pew Research Center polling on cannabis legalization: https://www.pewresearch.org/short-reads/2024/03/22/majority-of-americans-support-marijuana-legalization/
• ACLU report "A Tale of Two Countries: Racially Targeted Arrests in the Era of Marijuana Reform": https://www.aclu.org/report/tale-two-countries-racially-targeted-arrests-era-marijuana-reform
• BDSA cannabis market analytics and forecasts: https://bdsa.com/
• National Conference of State Legislatures state medical cannabis laws database: https://www.ncsl.org/health/state-medical-cannabis-laws